Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has a diagnosis of IBS-D, defined by the Rome III criteria as loose (mushy) or watery stools ≥25% and hard or lumpy stools ≤25% of bowel movements.~* Has had a colonoscopy performed within 5 years prior to Screening if they are at least 50 years of age, OR if they meet any of the following alarm features:~  1. Has documented weight loss within the past 6 months; or~ 2. Has nocturnal symptoms; or~ 3. Has a familial history of colon cancer; or~ 4. Has blood mixed with their stool (excluding any blood from hemorrhoids)~* Patient reports use of loperamide in the 12 months prior to Screening for IBS-D symptoms and that loperamide did not provide adequate control of IBS-D symptoms.~* Has not used any loperamide rescue medication within 14 days prior to randomization.~Exclusion Criteria:~* Has a diagnosis of Irritable Bowel Syndrome (IBS) with a subtype of constipation IBS, mixed IBS, or unsubtyped IBS.~* Has a history of inflammatory or immune-mediated gastrointestinal (GI) disorders including inflammatory bowel disease (i.e., Crohn's disease, ulcerative colitis), microscopic colitis, or celiac disease.~* Has a history of diverticulitis within 3 months prior to screening.~* Has a documented history of lactose intolerance.~* Has a documented history of bile-acid malabsorption.~* Has a history of chronic or severe constipation or intestinal obstruction, stricture, toxic megacolon, GI perforation, fecal impaction, gastric banding, bariatric surgery, adhesions.~* Has any of the following surgical history:~  1. Cholecystectomy or previously documented agenesis of gallbladder; or~ 2. Any abdominal surgery within the 3 months prior to screening; or~ 3. Major gastric, hepatic, pancreatic, or intestinal surgery (appendectomy, hemorrhoidectomy, or polypectomy greater than 3 months post-surgery are allowed).~* Has a history of cholecystitis within 6 months before screening.~* Has a history of pancreatitis or structural diseases of the pancreas, including known or suspected pancreatic duct obstruction.~* Has a history of known or suspected biliary duct obstruction or sphincter of Oddi disease or dysfunction, excluding a history of gallstones.~* Has a history or current evidence of laxative abuse within 5 years prior to screening.~* Has documented evidence of cirrhosis.~* Has a history of cardiovascular events, including stroke, myocardial infarction, congestive heart failure, or transient ischemic attack within 6 months prior to screening.~* Has an unstable renal, hepatic, metabolic, or hematologic condition.~* Has a history of malignancy within 5 years before screening (except squamous and basal cell carcinomas and cervical carcinoma in situ).~* Has a history of human immunodeficiency virus infection.~* Has a history of Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision-defined substance dependency, excluding nicotine and caffeine, within 2 years prior to screening.~* Has a history of alcohol abuse, alcohol addiction, and alcoholism or drinks more than 3 alcoholic beverages per day.~* Has used aspirin or aspirin-containing medications (\>325 mg of aspirin per day) or nonsteroidal anti-inflammatory drugs, when taken specifically for the symptoms of IBS, within 14 days of randomization.~* Has current (within 14 days of randomization) or expected use of any narcotic or opioid-containing agents, tramadol, docusate, enemas, GI preparations (including antacids containing aluminum or magnesium, antidiarrheal agents \[except loperamide rescue medication after randomization\]), antinausea agents, antispasmodic agents, bismuth, or prokinetic agents.~* Has current (within 28 days of randomization) use of rifaximin or other antibiotics (with the exception of topical antibiotics or a 1-day course with an antibiotic). Expected use of rifaximin or other antibiotics during the course of the study that is known at the time of randomization.~* Has an elective surgery planned or expects to need elective surgery at any time during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Eluxadoline (Type: ACTIVE_COMPARATOR): Eluxadoline 100 mg oral tablets twice daily (BID) with food for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matching eluxadoline oral tablets BID with food for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete